Cargando…

Optimal practices for the management of hereditary transthyretin amyloidosis: real-world experience from Japan, Brazil, and Portugal

Hereditary transthyretin (ATTRv) amyloidosis is a rare and autosomal dominant disorder associated with mutations in the transthyretin gene. Patients present with diverse symptoms related to sensory, motor, and autonomic neuropathy, as well as gastrointestinal, ocular, cardiac, renal and orthopedic s...

Descripción completa

Detalles Bibliográficos
Autores principales: Ando, Yukio, Waddington-Cruz, Marcia, Sekijima, Yoshiki, Koike, Haruki, Ueda, Mitsuharu, Konishi, Hiroaki, Ishii, Tomonori, Coelho, Teresa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10571420/
https://www.ncbi.nlm.nih.gov/pubmed/37828588
http://dx.doi.org/10.1186/s13023-023-02910-3
_version_ 1785119997510549504
author Ando, Yukio
Waddington-Cruz, Marcia
Sekijima, Yoshiki
Koike, Haruki
Ueda, Mitsuharu
Konishi, Hiroaki
Ishii, Tomonori
Coelho, Teresa
author_facet Ando, Yukio
Waddington-Cruz, Marcia
Sekijima, Yoshiki
Koike, Haruki
Ueda, Mitsuharu
Konishi, Hiroaki
Ishii, Tomonori
Coelho, Teresa
author_sort Ando, Yukio
collection PubMed
description Hereditary transthyretin (ATTRv) amyloidosis is a rare and autosomal dominant disorder associated with mutations in the transthyretin gene. Patients present with diverse symptoms related to sensory, motor, and autonomic neuropathy, as well as gastrointestinal, ocular, cardiac, renal and orthopedic symptoms, resulting from the deposition of transthyretin amyloid fibrils in multiple organs. The progressive nature of ATTRv amyloidosis necessitates pre- and post-onset monitoring of the disease. This review article is primarily based on a collation of discussions from a medical advisory board meeting in August 2021. In this article, we summarize the best practices in amyloidosis centers in three major endemic countries for ATTRv amyloidosis (Japan, Brazil, and Portugal), where most patients carry the Val30Met mutation in the transthyretin gene and the patients’ genetic background was proven to be the same. The discussions highlighted the similarities and differences in the management of asymptomatic gene mutation carriers among the three countries in terms of the use of noninvasive tests and tissue biopsies and timing of starting the investigations. In addition, this article discusses a set of practical tests and examinations for monitoring disease progression applicable to neurologists working in diverse medical settings and generalizable in non-endemic countries and areas. This set of assessments consists of periodic (every 6 to 12 months) evaluations of patients’ nutritional status and autonomic, renal, cardiac, ophthalmologic, and neurological functions. Physical examinations and patient-reported outcome assessments should be also scheduled every 6 to 12 months. Programs for monitoring gene mutation carriers and robust referral networks can aid in appropriate patient management in pre- to post-onset stages. For pre- and post-symptom onset testing for ATTRv amyloidosis, various noninvasive techniques are available; however, their applicability differs depending on the medical setting in each country and region, and the optimal option should be selected in view of the clinical settings, medical environment, and available healthcare resources in each region.
format Online
Article
Text
id pubmed-10571420
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-105714202023-10-14 Optimal practices for the management of hereditary transthyretin amyloidosis: real-world experience from Japan, Brazil, and Portugal Ando, Yukio Waddington-Cruz, Marcia Sekijima, Yoshiki Koike, Haruki Ueda, Mitsuharu Konishi, Hiroaki Ishii, Tomonori Coelho, Teresa Orphanet J Rare Dis Review Hereditary transthyretin (ATTRv) amyloidosis is a rare and autosomal dominant disorder associated with mutations in the transthyretin gene. Patients present with diverse symptoms related to sensory, motor, and autonomic neuropathy, as well as gastrointestinal, ocular, cardiac, renal and orthopedic symptoms, resulting from the deposition of transthyretin amyloid fibrils in multiple organs. The progressive nature of ATTRv amyloidosis necessitates pre- and post-onset monitoring of the disease. This review article is primarily based on a collation of discussions from a medical advisory board meeting in August 2021. In this article, we summarize the best practices in amyloidosis centers in three major endemic countries for ATTRv amyloidosis (Japan, Brazil, and Portugal), where most patients carry the Val30Met mutation in the transthyretin gene and the patients’ genetic background was proven to be the same. The discussions highlighted the similarities and differences in the management of asymptomatic gene mutation carriers among the three countries in terms of the use of noninvasive tests and tissue biopsies and timing of starting the investigations. In addition, this article discusses a set of practical tests and examinations for monitoring disease progression applicable to neurologists working in diverse medical settings and generalizable in non-endemic countries and areas. This set of assessments consists of periodic (every 6 to 12 months) evaluations of patients’ nutritional status and autonomic, renal, cardiac, ophthalmologic, and neurological functions. Physical examinations and patient-reported outcome assessments should be also scheduled every 6 to 12 months. Programs for monitoring gene mutation carriers and robust referral networks can aid in appropriate patient management in pre- to post-onset stages. For pre- and post-symptom onset testing for ATTRv amyloidosis, various noninvasive techniques are available; however, their applicability differs depending on the medical setting in each country and region, and the optimal option should be selected in view of the clinical settings, medical environment, and available healthcare resources in each region. BioMed Central 2023-10-12 /pmc/articles/PMC10571420/ /pubmed/37828588 http://dx.doi.org/10.1186/s13023-023-02910-3 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Review
Ando, Yukio
Waddington-Cruz, Marcia
Sekijima, Yoshiki
Koike, Haruki
Ueda, Mitsuharu
Konishi, Hiroaki
Ishii, Tomonori
Coelho, Teresa
Optimal practices for the management of hereditary transthyretin amyloidosis: real-world experience from Japan, Brazil, and Portugal
title Optimal practices for the management of hereditary transthyretin amyloidosis: real-world experience from Japan, Brazil, and Portugal
title_full Optimal practices for the management of hereditary transthyretin amyloidosis: real-world experience from Japan, Brazil, and Portugal
title_fullStr Optimal practices for the management of hereditary transthyretin amyloidosis: real-world experience from Japan, Brazil, and Portugal
title_full_unstemmed Optimal practices for the management of hereditary transthyretin amyloidosis: real-world experience from Japan, Brazil, and Portugal
title_short Optimal practices for the management of hereditary transthyretin amyloidosis: real-world experience from Japan, Brazil, and Portugal
title_sort optimal practices for the management of hereditary transthyretin amyloidosis: real-world experience from japan, brazil, and portugal
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10571420/
https://www.ncbi.nlm.nih.gov/pubmed/37828588
http://dx.doi.org/10.1186/s13023-023-02910-3
work_keys_str_mv AT andoyukio optimalpracticesforthemanagementofhereditarytransthyretinamyloidosisrealworldexperiencefromjapanbrazilandportugal
AT waddingtoncruzmarcia optimalpracticesforthemanagementofhereditarytransthyretinamyloidosisrealworldexperiencefromjapanbrazilandportugal
AT sekijimayoshiki optimalpracticesforthemanagementofhereditarytransthyretinamyloidosisrealworldexperiencefromjapanbrazilandportugal
AT koikeharuki optimalpracticesforthemanagementofhereditarytransthyretinamyloidosisrealworldexperiencefromjapanbrazilandportugal
AT uedamitsuharu optimalpracticesforthemanagementofhereditarytransthyretinamyloidosisrealworldexperiencefromjapanbrazilandportugal
AT konishihiroaki optimalpracticesforthemanagementofhereditarytransthyretinamyloidosisrealworldexperiencefromjapanbrazilandportugal
AT ishiitomonori optimalpracticesforthemanagementofhereditarytransthyretinamyloidosisrealworldexperiencefromjapanbrazilandportugal
AT coelhoteresa optimalpracticesforthemanagementofhereditarytransthyretinamyloidosisrealworldexperiencefromjapanbrazilandportugal